A new test developed by UBC researchers allows physicians to measure the effects of gene silencing therapy in Huntington’s disease and will support the first human clinical trial of a drug that targets the genetic cause of the disease.
UBC Okanagan biology professor Blythe Nilson applauds Health Canada’s upgrade to the labeling of nosodes, or homeopathic products regulated by the Natural and Non-prescription Health Products Directorate (NNHPD).
